Please®a global leader in AI-based pathology solutions for precision medicine, has expanded its leadership position in the pathology diagnostics market. The company has increased its clinical customer base by more than 100% in the past year. Among its other achievements, Proscia has been recognized by KLAS Research in Emerging Company Spotlight Report June 2024 and released the research results conducted with Quest Diagnostics, a leading provider of diagnostic information services, on the impact of its AI-powered workflows.
Proscia’s momentum comes as digital pathology experiences a modern surge in demand worldwide. Labs are increasingly looking to grow their businesses by leveraging real-world data generated as they go from the microscope to imaging; each full slide image contains more than 1 billion pixels that could accelerate the development of the next blockbuster therapies. With Concentriq® The Proscia software platform enables laboratories to fully leverage data while optimizing operations and creating the foundation for modern insights through AI applications.
KLAS Emerging Company Spotlight Confirms Concentriq Delivers Immediate Value and Customers Trust Proscia
Early data from KLAS shows that the majority of Proscia customers surveyed saw immediate benefits from Concentriq, with all such customers achieving results within 6 months of implementing the enterprise pathology platform. These include reduced lead times, attracting more talent, and creating a real-world data archive to drive research and development.
The KLAS report further reveals that customers are impressed with both the level of support they receive and Proscia’s expertise in pathology. They also gave Proscia an “A+” rating for the commitment of its management team. Working with a trusted partner who offers a world-class software platform has led to 100% of Proscia customers surveyed saying they would purchase again.
Read the KLAS Research Emerging Company Spotlight on Concentriq and access the full report Here.
Quest Diagnostics study highlights Concentriq’s scalable approach to AI
By leveraging Concentriq’s AI-powered workflows with Ibex’s AI-powered Prostate* clinical solution, Quest Diagnostics pathologists were able to capture 2.9 cases per hour instead of 1.2. The solution is designed to aid pathologists improve prostate cancer detection and staging by streamlining the process of pathologists reviewing high-resolution scanned tissue samples to create digital slides or whole slide images (WSIs), which pathologists can then review.
The study included 180 random adult prostate cases (age 21 or older). 100% of pathologists who participated in the study said they were significantly more likely to accept AI after the study was completed. Quest Diagnostics, through its subspecialty pathology businesses AmeriPath and Dermpath Diagnostics, employs more than 400 pathologists in its nationwide network of clinical laboratories.
View and download the entire study Here.
Recent FDA clearance allows Proscia to introduce its software into the pathology diagnostics market in the US
In February, Proscia received FDA 510(k) clearance for its Concentriq AP-Dx** solution for primary diagnostics. This milestone not only opened the U.S. pathology diagnostics market for Proscia, but also enabled its distribution partners Agilent Technologies and Siemens Healthineers to provide the software to their U.S. customers.
Proscia’s 510(k) certification further strengthens its regulatory credentials. It was the first company to receive CE-IVDR certification to promote primary digital pathology diagnostics in the European Union, and its products are licensed in Canada and approved in the United Kingdom, as well as in other countries.
“More and more labs trust Proscia to help them deliver faster results, make confident diagnoses and grow their businesses, especially now that we have FDA clearance,” said David West, CEO. “It’s incredibly rewarding to see the impact our Concentriq platform and team are having. This is evidenced by the positive feedback our customers have shared with KLAS, as well as the impressive results from Quest Diagnostics.”
*The Ibex package includes solutions that are intended for Investigational Employ Only (RUO) in the United States and are not FDA approved. Many of the solutions are CE marked (IVDD and IVDR) and registered with the UK MHRA. For more information, including indication for apply and regulatory approval in other countries, contact Ibex Medical Analytics.
**Concentriq AP-Dx is approved (K230839) for clinical apply with the Hamamatsu NanoZoomer S360MD slide scanner in the United States.